Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and healt...
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)
About this item
Full title
Author / Creator
Wagner, Lynne I. , Zhao, Fengmin , Goss, Paul E. , Chapman, Judith-Anne W. , Shepherd, Lois E. , Whelan, Timothy J. , Mattar, Bassam I. , Bufill, Jose A. , Schultz, William C. , LaFrancis, Irving E. , Nagargoje, Gauri G. , Vemuri, Radhakrishna , Nikcevich, Daniel A. , Sledge, George W. and Cella, David
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Purpose
Aromatase inhibitors are the most commonly prescribed adjuvant endocrine therapy for hormone-dependent early breast cancer in postmenopausal women. Among Canadian Cancer Trials Group MA.27 participants, anastrozole and exemestane had comparable 5-year event-free survival. This companion study examined differences in patient-reported trea...
Alternative Titles
Full title
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6092930
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6092930
Other Identifiers
ISSN
0167-6806,1573-7217
E-ISSN
1573-7217
DOI
10.1007/s10549-018-4713-2
